Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors
摘要:
The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)4(Z)-(methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.
Synthesis of substituted 4(Z)-(methoxyimino)pentyl-1-piperidines as dual NK1/NK2 inhibitors
摘要:
The NK1 and NK2 receptor activity of a series of 5-[(3,5-bis(trifluoromethyl)phenyl)methoxy]-3-(3,4-dichlorophenyl)4(Z)-(methoxyimino)pentyl-1-piperidines was evaluated. Compounds 11d, 11e, 11f, 12a, and 12k were found to be our most potent inhibitors. (C) 2001 Elsevier Science Ltd. All rights reserved.
5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST
申请人:ZENECA LIMITED
公开号:EP0808303A1
公开(公告)日:1997-11-26
[EN] 5-(4-SUBST.-PIPERIDINYL-1)-3-ARYL-PENTANOIC ACID DERIVATIVES AS TACHYKININ RECEPTOR ANTAGONIST<br/>[FR] DERIVES D'ACIDE 5-(4-SUBSTITUE-PIPERIDINYL-1)-3-ARYL-PENTANOIQUE UTILISES COMME ANTAGONISTES DES RECEPTEURS DE LA TACHYKININE
申请人:ZENECA LIMITED
公开号:WO1996024582A1
公开(公告)日:1996-08-15
(EN) Compounds of formula (I), wherein Q1, Q2, Q3 and Q4 have any of the meanings given in the specification, their N-oxided, and their pharmaceutically acceptable salts are nonpeptide antagonists of SP and NKA, useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula (I) and intermediates.(FR) La présente invention concerne des composés représentés par la formule (I) dans laquelle Q1, Q2, Q3 et Q4 ont les significations données dans la description de l'invention, des N-oxydes ainsi que des sels pharmaceutiquement acceptables de ces composés, qui sont des antagonistes non peptidiques de SP et de la neurokinine A (NKA) et sont utiles pour le traitement de l'asthme, etc. L'invention se rapporte également à des compositions pharmaceutiques contenant les composés de la formule (I) ainsi qu'à des procédés de préparation de ces composés et de leurs intermédiaires.